Citations

Showing 10 of 108162 citations.

Harris Platelet Syndrome— Underdiagnosed and Unrecognized
Naina, Harris, Harris, Samar

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 132 | Issue: 10 | Pages: 1546

10.5858/2008-132-1546a-hpsuau | PMID 18834201 Get It

Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: A single‐center experience
Shabtaie, Samuel A. , Witt, Chance M. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 10, 2021 | Volume: 32 | Issue: 4 | Pages: 1053-1061

10.1111/jce.14942 | PMID 33566447 Get It

AbstractBackgroundEffective therapy for inappropriate sinus tachycardia (IST) remains challenging with high rates of treatment failure and symptom recurrence. It is uncertain how effective pharmacotherapy and procedural therapy are long‐term, with poor response to medical therapy in general.MethodsWe retrospectively reviewed all patients with the diagnosis of IST at a tertiary academic medical center from 1998 to 2018. We extracted data related to prescribing patterns and symptom response to medical therapy and sinus node modification (SNM), assessing efficacy and periprocedural complication rates.ResultsA total of 305 patients with a formal diagnosis of IST were identified, with 259 (84.9%) receiving at least one prescription medication related to the condition. Beta‐blockers were the most commonly used medication (n = 245), with a majority of patients reporting no change or worsening of symptoms, and poor response was seen to other medication classes. Improvement was seen significantly more often with ivabradine than beta blockers, though the sample size was limited (p = .003). Fifty‐five patients (18.0% of all IST patients), mean age 32.0 ± 9.1 years, underwent a SNM procedure, with an average of 1.8 ± 0.9 procedures per patient. Acute symptomatic improvement (<6 months) was seen in 58.2% of patients. Long‐term complete resolution of symptoms was seen in 5.5% of patients, modest improvement in 29.1%, and no long‐term benefit was seen in 65.5% of patients.ConclusionsAmong all medical therapies, there were high rates of treatment failure or symptom worsening in over three‐quarters of patients in our study. Ivabradine was most beneficial, though the sample size was small. While most patients receiving SNM ablation for IST perceive an acute symptomatic improvement, almost two‐thirds of patients have no long‐term improvement, and resolution of symptoms is quite rare. AV node ablation with pacemaker implantation following lack of response to SNM offered increased success, though the sample size was limited.
How Sensitive Is a Prostate-Specific Antigen Measurement?: How Sensitive Does It Need to Be?
Bock, Jay L., Klee, George G.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 3 | Pages: 341-343

10.5858/2004-128-341-hsiapa | PMID 14987148 Get It

Abstract Assays are now available that can measure very low concentrations of prostate-specific antigen (PSA), but their analytic performance and clinical utility are not well defined. This brief article highlights some of the clinical issues related to the limited prognostic significance of small changes in PSA concentrations in men with prostate cancer who have been treated with prostate ablation therapy. College of American Pathologists proficiency survey data are presented, illustrating the performance of commercial PSA assays with low PSA concentration survey samples tested between 1998 and 2002. The performance of the assays appears to be improving, but many of the currently used assays have intralaboratory coefficients of variation greater than 20% for PSA concentrations less than 0.4 ng/mL. Also, there are major differences in the level of PSA reported by various assays in these low concentration samples. These level differences (if they are also seen in clinical samples) may cause clinical problems when fixed serum PSA thresholds (eg, 0.2 ng/mL) are used to make clinical decisions related to prostate tumor recurrence.
Diagnostic Problems in Anatomic Pathology
Leslie, Kevin O.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 131 | Issue: 3 | Pages: 358-359

10.5858/2007-131-358-dpiap Get It

Biochemical Markers of Myocardial Injury Test Turnaround Time: A College of American Pathologists Q-Probes Study of 7020 Troponin and 4368 Creatine Kinase–MB Determinations in 159 Institutions
Novis, David A., Jones, Bruce A., Dale, Jane C., Walsh, Molly K.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 2 | Pages: 158-164

10.5858/2004-128-158-bmomit | PMID 14736289 Get It

Abstract Context. —Rapid diagnosis of acute myocardial infarction in patients presenting to emergency departments (EDs) with chest pain may determine the types, and predict the outcomes of, the therapy those patients receive. The amount of time consumed in establishing diagnoses of acute myocardial infarction may depend in part on that consumed in the generation of the blood test results measuring myocardial injury. Objective. —To determine the normative rates of turnaround time (TAT) for biochemical markers of myocardial injury and to examine hospital and laboratory practices associated with faster TATs. Design. —Laboratory personnel in institutions enrolled in the College of American Pathologists Q-Probes Program measured the order-to-report TATs for serum creatine kinase–MB and/or serum troponin (I or T) for patients presenting to their hospital EDs with symptoms of acute myocardial infarction. Laboratory personnel also completed detailed questionnaires characterizing their laboratories' and hospitals' practices related to testing for biochemical markers of myocardial injury. ED physicians completed questionnaires indicating their satisfaction with testing for biochemical markers of myocardial injury in their hospitals. Setting. —A total of 159 hospitals, predominantly located in the United States, participating in the College of American Pathologists Q-Probes Program. Results. —Most (82%) laboratory participants indicated that they believed a reasonable order-to-report TATs for biochemical markers of myocardial injury to be 60 minutes or less. Most (75%) of the 1352 ED physicians who completed satisfaction questionnaires believed that the results of tests measuring myocardial injury should be reported back to them in 45 minutes or less, measured from the time that they ordered those tests. Participants submitted TAT data for 7020 troponin and 4368 creatine kinase–MB determinations. On average, they reported 90% of myocardial injury marker results in slightly more than 90 minutes measured from the time that those tests were ordered. Among the fastest performing 25% of participants (75th percentile and above), median order-to-report troponin and creatine kinase–MB TATs were equal to 50 and 48.3 minutes or less, respectively. Shorter troponin TATs were associated with performing cardiac marker studies in EDs or other peripheral laboratories compared to (1) performing tests in central hospital laboratories, and (2) having cardiac marker specimens obtained by laboratory rather than by nonlaboratory personnel. Conclusion. —The TAT expectations of the ED physicians using the results of laboratory tests measuring myocardial injury exceed those of the laboratory personnel providing the results of those tests. The actual TATs of myocardial injury testing meet the expectations of neither the providers of those tests nor the users of those test results. Improving TAT performance will require that the providers and users of laboratory services work together to develop standards that meet the needs of the medical staff and that are reasonably achievable by laboratory personnel.
Pathologic Quiz Case: A 56-Year-Old Man With Bilateral Renal Masses
Dimashkieh, Haytham, Blute, Michael L., Lager, Donna J. , Dimashkieh, Haytham H, Jevremović, Dragan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 12 | Pages: e177-e178

10.5858/2004-128-e177-pqcaym | PMID 15578907 Get It

Percutaneous liquid ablation agent for tumor treatment and drug delivery
Albadawi, Hassan , Zhang, Zefu , Altun, İzzet , Hu, Jingjie , Jamal, Leila , Ibsen, Kelly N. , Tanner, Eden E. L. , Mitragotri, Samir , Öklü, Rahmi , Oklu, Rahmi , Jamal, Leila

Mayo Clinic

Science Translational Medicine | February 10, 2021 | Volume: 13 | Issue: 580 | Pages: No page available

10.1126/scitranslmed.abe3889 | PMID 33568519 Get It

An ionic liquid formulation ablates tumors, uniformly distributes drugs in the ablation zone, and has synergistic effects with chemotherapy.
MUC1 Gene–Derived Glycoprotein Assays for Monitoring Breast Cancer (CA 15-3, CA 27.29, BR): Are They Measuring the Same Antigen?
Klee, George G., Schreiber, William E.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 10 | Pages: 1131-1135

10.5858/2004-128-1131-mggafm | PMID 15387710 Get It

Abstract Context. —There are 2 general types of assays measuring MUC1 gene–derived glycoprotein: assays for cancer antigen (CA) 15-3, which are sandwich assays, and assays for CA 27.29, which are competitive assays. These 2 types of assays measure slightly different parts of this tandem-repeat molecule. Across-method assay differences hinder the exchange of patient test values among integrated health care networks and among countries. Objective. —This report evaluates the method differences among these assays to determine if the differences between these assays are mainly related to variations in calibration or differences in analyte specificity. Design. —Data from 22 College of American Pathologists survey challenges were analyzed to compare 10 commercial assay methods for these 2 related analytes. In addition, data from 58 patient samples were analyzed to compare 3 of these assays. Results. —The linear correlation coefficients comparing the within-method medians of these proficiency test distributions were very high (>0.99) for all of the methods; however, the regression slopes varied from 0.836 to 1.095. The regression slopes for the patient specimens varied similarly, but the correlation coefficients were lower. Conclusions. —This study indicates that many of the test value differences for these measurements are due to differences in assay calibration rather than differences in the specificity of the assay measurement systems. Survey test data potentially could be used to help harmonize these assay differences.
McIsaac score for group A streptococcal infection: Comparison of electronic visits versus face-to-face visits
Miller, Nathaniel E. , Jensen, Teresa B. , Nigon, Leah M , Penza, Kristine S , Murray, Martha A. , Kronebusch, Beckie J , Pecina, Jennifer L. , Miller, Nathaniel E , Pecina, Jennifer

Mayo Clinic

Journal of Telemedicine and Telecare | February 10, 2021 | Volume: 29 | Issue: 6 | Pages: 492-497

10.1177/1357633x21990999 | PMID 33535918 Get It

Introduction Acute sore throat is a common complaint traditionally completed with an in-person visit. However, non-face-to-face telemedicine visits offer greater access at reduced cost. We evaluated patient/caregiver asynchronous text-based electronic visits (eVisits) for acute sore throat and whether there was concordance for individual components and total McIsaac score compared to a clinician’s assessment. eVisits were completed by patients and/or their caregivers via a secure patient portal. Methods In this retrospective study, we manually reviewed charts between February 2017 and July 2019 of patients who had an eVisit, in-person visit and group A streptococcal (GAS) test performed on the same day for an acute sore throat. We calculated a McIsaac score for eVisits and in-person visits, and compared each component and total score using Cohen’s kappa agreement statistic. Results There were 320 instances of patients who had an eVisit, in-person visit and GAS testing done on the same day. Approximately a third of eVisits were missing at least one McIsaac component, with the physical examination elements missing most commonly. Individual score congruence was moderate for cough (0.41), fair for fever (0.34) and slight for tonsillar swelling/exudate and lymphadenopathy (0.17 and 0.08, respectively), with total congruence being slight to fair (0.09–0.37). A McIsaac score of ≤1 showed moderate agreement (0.44). Visits with complete individual score components demonstrated improved congruence: substantial for cough (0.64), moderate for fever (0.57), fair for tonsillar swelling (0.3) and slight for lymphadenopathy (0.13). Discussion Overall agreement for individual score components was better for symptoms than it was for examination components, and was improved when data were complete. A McIsaac score of 1 or 0 had moderate agreement and thus could reasonably be safely used to exclude patients from GAS testing.
Human Anti-Mouse Antibodies
Klee, George G.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 124 | Issue: 6 | Pages: 921-923

10.5858/2000-124-0921-hama | PMID 10835540 Get It

Abstract Human anti-mouse antibodies (HAMA) are human immunoglobulins with specificity for mouse immunoglobulins. This topic currently is of interest because of the increased use of monoclonal mouse antibodies as diagnostic reagents both for in vitro laboratory measurements and for in vivo imaging studies. Monoclonal mouse antibodies also are being used therapeutically. This short article reviews the production of HAMA in patients receiving monoclonal antibodies and illustrates the potential ways that HAMA can interfere with immunoassay measurements. Methods for measuring and neutralizing HAMA also are discussed.